Product Description: MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29?μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52?μM and unstresses RPMI 8226 cells with an IC50 of 0.14?μM[1]. MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth[2].
Applications: Cancer-programmed cell death
Formula: C18H19NO7
References: [1]Sheng X, et al. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019 Jan 24;10(1):323./[2]Logue SE, et al. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat Commun. 2018 Aug 15;9(1):3267.
CAS Number: 1338934-59-0
Molecular Weight: 361.35
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : 6.67 mg/mL (ultrasonic;warming;heat to 60°C)
Target: IRE1
English
Deutsch
